5-HT1 receptor augmentation strategies as enhanced efficacy therapeutics for psychiatric disorders

Current Topics in Medicinal Chemistry

Volumn 8, Issue 12, 2008, Pages 1008-1023

  Dawson, Lee A ^a   Bromidge, Steve M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT1A; 5 HT1B; 5 HT1D; Add on; Anxiety; Autoreceptor; Depression; Serotonin (5 HT); Serotonin specific reuptake inhibitor (SSRI); Serotonin transporter (SERT)

Indexed keywords

[1 [3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL]PROPYL] 5 METHOXY 3,4 DIHYDRO 2 QUINOLONE MONOMETHANESULFONATE]; ANTIDEPRESSANT AGENT; AP 521; AZD 8129; BMS 296859; BUSPIRONE; CITALOPRAM; FLUOXETINE; LECOZOTAN; LU 36 274; LY 433221; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NDL 249; OPC 14523; PAROXETINE; PINDOLOL; PLACEBO; ROBALZOTAN; SB 649915; SEROTONIN 1 RECEPTOR; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN 1D ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN TRANSPORTER; SEROTONIN TRANSPORTER INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SSA 426; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILAZODONE; VN 2222; SEROTONIN;

ALZHEIMER DISEASE; ANXIETY DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DEPRESSION; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; MENTAL DISEASE; MONOTHERAPY; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN TARGETING; REVIEW; SEROTONINERGIC TRANSMISSION; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; VOMITING; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; STRUCTURE ACTIVITY RELATION;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MOLECULAR STRUCTURE; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 52949147789     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608785161439     Document Type: Review

References (161)

1. Rapaport, M.M.; Green, A.A.; Page, I.H. Purification of the substance which is responsible for vasoconstriction activity of serum. Fed. Proceeds. 1947, 6, 184.
2. Feldberg, W.; Myers, W.F. Effects on temperature of 5-hydroxtryptamine, adrenaline and noradrenaline injected into the cerebral ventricles of the hypothalamus of cats. J. Physiol. 1964, 173, 25-30.
3. Jouvet, M. Neurophysiology of the states of sleep. Physiol. Rev. 1967, 47, 117-177.
4. Tenen, S.S. The effects of p-chlorophenylalanine, a serotonin depletor, on avoidance acquisition, pain sensitivity and related behaviour in the rat. Psychopharmacol. 1967, 10, 204-219.
5. Fernstrom, J.D.; Wurtman, R.J. Brain serotonin content: Increase following ingestion of carbohydrate diet. Science 1971, 174, 1023-1025.
6. Gorzalka, B.B.; Mendelson, S.D.; Watson, N.V. Serotonin receptor subtypes and sexual behaviour. Ann. N.Y. Acad. Sci. 1990, 600, 435-446.
7. Golden, R.N.; Gilmore, J. Serotonin and mood disorders. Psychiatr. Ann. 1990, 20, 580-586.
8. Dahlstrom, A.; Fuxe, K. Evidence for the existence of monamine-containing neurones in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurones. Acta Physiol. Scand. 1964, 62, Suppl. 232.
9. Hoyer, D.; Clarke, D.E.; Fozard, J.R.; Hartig, P.R.; Martin, G.R.; Mylecharane, E.J.; Saxena, F.R.; Humphrey, P.P.A. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994, 46, 157-243
10. Jacobs, B.L.; Azmitia, E.C. Structure and function of the brain serotonin system. Physiol. Rev. 1992, 72, 165-229
11. 1B agonists. Synapse 1987, 1, 3-9
12. 1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987, 1, 470-480.
13. Aghajanian, G.K.; Lakoski, J.M. Hyperpolarisation of serotonergic neurons by serotonin and LSD: Studies in brain slices showing increased K conductance. Brain Res. 1984, 305, 181-185.
14. 1A autoreceptor interactions in the rat dorsal raphe nucleus: An in vitro electrophysiological study. Neurosci. 1991, 41, 495-505.
15. 1A receptor in the rat brain: Correlation with receptor binding. J. Neurosci. 1992, 12, 440-453.
16. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neurosci. 1991, 40, 399-412.
17. 1A receptors control 5-HT release in the rat medial prefrontal cortex. NeuroReport 1999, 10, 1441-1445.
18. Celada P.; Puig M.V.; Martin-Ruiz, R.; Casanovas J.M.; Artigas, F. Control of the serotonergic system by the medial prefrontal cortex: potential role in the etiology of PTSD and depressive disorders. Neurotox Res. 2002, 4, 409-419.
19. Santana, N.; Bortolozzi, A.; Serrats, J.; Mengod, G.; Artigas, F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2004, 14, 1100-1109.
20. 1D receptor in rat and human brain. J. Neurochem. 1988, 50, 1624-1831.
21. 1D receptors in the human brain using a new iodinated ligand. Mol. Brain Res. 1992, 346, 175-179.
22. 1B binding sites in rat brain. Nauyn Schmid. Arch. Pharmacol. 1993, 347, 569-582.
23. Doucet, E.; Pohl, M.; Fattaccini, C.M.; Adrien, J.; Mestikawy, S.E.; Hamon M. In situ hybridization evidence for the synthesis of 5-HT1B receptor in serotoninergic neurons of anterior raphe nuclei in the rat brain. Synapse 1995, 19, 18-28.
24. 1D autoreceptors. Neuropharmacol. 1996, 35, 1627-1634.
25. 1B receptor selectivity for 5-HT terminal autoreceptor activity: An in vivo microdialysis study in the freely-moving guinea-pig. Neuropharmacol. 1997, 36, 549-557.
26. 1B/1D receptors in the modulation of 5-hydroxytryptamine levels in the frontal cortex of the conscious guinea pig. Eur. J. Pharmacol. 1997, 326, 23-30.
27. 1D autoreceptors. Br. J. Pharmacol. 1905, 114, 1107-1109.
28. Woolley, D.W.; Shaw, E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. USA 1954, 40, 228-231.
29. Abi-Dargham, A.; Laruelle, M.; Aghajanian, G.K.; Charney, D.; Krystal, J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiatr. Clin. Neurosci. 1997, 9, 1-17.
30. Zohar, J.; Mueller, E.A.; Insel, T.R.; Zohar-Kadouch, R.C.; Murphy, D.L. Serotonin responsivity in obsessive-compulsive disorder. Arch. Gen. Psychiatr. 1987, 44, 946-951.
31. Zohar, J.; Zohar-Kadouch, R.C.; Kindler, S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 1992, 43, 210-218.
32. Briley, M.; Chopin, P. Serotonin in anxiety. Evidence from animal models. In: Sandler, M.; Coppen, A.,, Harnett, S. (Eds.), 5- Hydroxytryptamine in Psychiatry: A spectrum of ideas. Oxford Univ. Press, Oxford, 1991, 177-197.
33. Briley, M.; Chopin, P. Is anxiety associated with hyper or pyposerotonergic state? In: Palomo, T., Archer, T. (Eds.), Strategies for studying brain disorders, depression, anxiety and drug abuse disorders, vol. 1, Editorial Complutence, Donoso Cortes, Madrid, 1994, 197-209.
34. Goodwin, F.K.; Bunney, W.E. Jr. Depressions following reserpine: A reevaluation. Semin Psychiatry 1971, 3, 435-448
35. Coppen, A.; Shaw, D.M.; Malleson, A.; Eccleston, E.; Gundy G. Tryptamine metabolism in depression. Br. J. Psychiatr. 1965, 111, 993-998.
36. Coppen, A.; Shaw, D.M.; Herzberg, B.; Maggs, R. Tryptophan in the treatment of depression. Lancet 1967, 2, 1178-1180.
37. Shopsin, B. Enhancement of the antidepressant response to L-tryptophan by a liver pyrrolase inhibitor: A rational treatment. Neuropsychobiol. 1978, 4, 188-192.
38. Delgado, J.M.R.; Charney, D.S.; Price, L.H.; Aghajanian, G.K.; Landis, H.; Heninger, G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant - induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Physchiatr. 1990, 47, 411-418.
39. Serretti, A.; Calati, R.; Mandelli, L.; De Ronchi, D. Serotonin transporter gene variants and behavior: A comprehensive review. Curr. Drug Targets 2006, 7, 1659-1669.
40. Artigas, F.; Perez, V.; Alvarez E. Pindolol induces a rapid improvement of patients with depression treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatr. 1994, 51, 248-251.
41. Blier, P.; Bergeron, R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 1995, 15, 217-222.
42. Svensson, T.H. Attenuated feed-back inhibition of brain serotonin synthesis following chronic administration of imipramine. Naunyn-Schmiedeberg's Arch. Pharmacol. 1978, 302, 115-118
43. 1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987, 1, 470-480.
44. Blier, P.; De Montigny, C.; Chaput, Y. Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 1987, 7, 24-35.
45. Dawson, L.A.; Nguyen, H.Q.; Smith, D.L.; Schechter, L.E. Effects of chronic fluoxetine treatment, in the presence and absence (±) pindolol: A microdialysis study. Br. J. Pharmacol. 2000, 130, 797-804.
46. Dawson, L.A.; Nguyen, H.Q.; Smith, D.I.; Schechter, L.E. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. J. Psychopharmacol. 2002, 16, 145-152.
47. 1A autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635. Neuropsychopharmacol. 2001, 24, 11-20.
48. Blier, P.; Chaput, Y.; De Montigny, C. Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: An electrophysiological study in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 1988, 337, 246-254.
49. 1B mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacol. 1996, 15, 515-522
50. 1D) in the human brain by autoradiography. Neurosci. Lett. 1988, 88, 11-16.
51. 1F receptor messenger RNA in rodent and primate brain. Neuropharmacol. 1994, 33, 367-86.
52. Spinks, D.; Spinks, G. Serotonin reuptake inhibition: An update on current research strategies. Curr. Med. Chem. 2002, 9, 799-810.
53. Bymaster, F.P.; McNamara, R.K.; Tran, P.V. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opin. Investig. Drugs 2003, 12, 531-543.
54. Bosker, F.J.; Westerink, B.H.; Cremers, T.I.; Gerrits, M.; van der Hart, M.G.; Kuipers, S.D.; van der Pompe, G.; ter Horst, G.J.; den Boer, J.A.; Korf, J. Future antidepressants: What is in the pipeline and what is missing? CNS Drugs 2004, 18, 705-732.
55. Moltzen, E.K.; Bang-Andersen, B. Serotonin reuptake inhibitors: The corner stone in treatment of depression for half a century - a medicinal chemistry survey. Curr. Top. Med. Chem. 2006, 6, 1801-1823.
56. McAskill, R.; Mir, S.; Taylor D. Pindolol augmentation of antidepressant therapy. Br. J. Psychiatry 1998, 173, 203-208.
57. Artigas, F.; Adell, A.; Celada, P. Pindolol augmentation of antidepressant response. Curr. Drug Targets 2006, 7, 139-147.
58. 1A autoreceptor in vivo. Br. J. Pharmacol. 1998, 124, 206-212.
59. Rabiner, E.A.; Bhagwagar, Z.; Gunn, R.N.; Sargent, P.A.; Bench, C.J.; Cowen, P.J.; Grasby, P.M. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am. J. Psychiatr. 2001, 158, 2080-2082.
60. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacol. 1996, 15, 349-360.
61. 1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci. Lett. 1996, 219, 123-126.
62. 1A (auto) receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacol. 1997, 36, 461-465.
63. 1A receptor antagonists on fluoxetine-induced changes in serotonin in rat frontal cortex. Eur. J. Pharmacol. 1998, 345, 41-46.
64. 1A receptors. Neurochem. Res. 1996, 21, 557-562.
65. Hjorth, S. (-) Pindolol, but not buspirone, potentiates the citalopram - induced rise in extracellular 5-hydroxytryptamine. Eur. J. Pharmacol. 1996, 303, 183-186.
66. 1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav. Brain Res. 1996, 73, 281-283.
67. 1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: The mechanism of action of (±)pindolol. Neuropharmacol. 2000, 39, 1044-1052.
68. 1B receptor antagonists. Pharmacol Biochem Behav. 2004, 77, 69-75.
69. 1A receptor antagonist WAY-100635. Br. J. Pharmacol. 2000, 130, 1713-1719.
70. 1A receptor antagonist, WAY-100635. Eur. J. Pharmacol. 1995, 281, 81-86.
71. 1A receptor antagonist. Behav. Brain Res. 1996, 73, 337-341.
72. 1-adrenoceptors. Autonom. Autacoid. Pharmacol. 2005, 25, 185-189.
73. 1A receptor ligands, LY293284, LY315712 and LY297996, on plusmaze anxiety in mice. Psychopharmacologia 1998, 139, 185-194
74. 1A receptor antagonists, WAY-100 635 and NDL-249, stimulate locomotion in rats acclimatised to their environment and alter their behaviour: A behavioural analysis. Psychopharmacol. 1998, 139, 300-310.
75. 1A Receptor. J. Med. Chem. 2000, 43, 2837-2850.
76. 1A receptor antagonist, NAD-299. J. Pharmacol. Exp. Therap. 1997, 283, 216-225.
77. 1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively. Eur. J. Pharmacol. 1993, 230, 99-102.
78. 1A antagonists. J. Pharmacol. Exp. Therap. 1994, 268, 337-352.
79. 1A Receptors in a Series of N4-Substituted Arylpiperazines. J. Med. Chem. 1995, 38, 4044-4055.
80. 1A Antagonists: The Discovery of Lecozotan. J.Med. Chem. 2005, 48, 3467-3470.
81. Schechter, L.E.; Smith, D.L.; Rosenzweig-Lipson, S.; Sukoff, S.; Dawson, L.A.; Marquis, K.; Jones, D.; Piesla, M.; Andree, T.; Harder, J.; Womack, M.D.; Buccafusco, J.; Terry, A.V.; Hoebel, B.; Rada, P.; Kelly, M.; Abou-Gharbia, M.; Barrett, J.E.; Childers, W. Lecozotan (SRA-333): A selective serotonin1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and promotes procognitive effects. J. Pharmacol. Exp. Ther. 2005, 314, 1274-1289.
82. Mucke, H.A. Robalzotan AstraZeneca. Curr. Opin. Investig. Drugs 2000, 1, 236-240.
83. 1A receptor antagonist NAD-299. Results from an 8 week placebo and paroxetine controlled - study. Eur. J. Neuropsychopharmacol. 2003, 13, Suppl. 189.
84. 1A antagonist component into a class of serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 307-310.
85. 1A and serotonin transporter affinity within a class of N- aryloxyethylindolylalkylamines. J. Med. Chem. 2004, 47, 3823-3842.
86. Tran, M.; Stack, G.P. Preparation of antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline. WO 2002072587 2002.
87. Stack, G.P.; Gao, H.; Gildersleeve, E.S. Preparation of antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans. US 2003162805 2003.
88. 1A antagonists as future antidepressant agents: A neurochemical assessment of WAY-163426. Soc. Neurosci. Abstr. 2004, 30, 1024.14.
89. 1A antagonist for the treatment of depression. Abstr.233rd ACS National Meeting 2007.
90. 1A receptor and serotonin transporter affinity. Bioorg. Med. Chem. Lett. 2006, 16, 1338-1341.
91. 1A receptor. Bioorg. Med. Chem. Lett. 2007, 17, 3117-3121.
92. 1A receptor antagonist and potential novel antipdepressant. Soc. Neurosci. Abstr. 2006, 32, 828.1.
93. 1A receptor antagonism/SSRI activities. Part 1. Bioorg. Med. Chem. Lett. 2003, 13, 1903-1905.
94. 1A receptor antagonism/SSRI activities. Part 2. Bioorg. Med. Chem. Lett. 2003, 13, 2393-2397.
95. 1A receptor antagonism/SSRI activities. Part 3. Bioorg. Med. Chem. Lett. 2003, 13, 3939-3942.
96. 1A receptor antagonism/SSRI activities. Part 5. Bioorg. Med. Chem. Lett. 2006, 1, 2347-2351.
97. Rocco, V.P.; Spinazze P.G.; Kohn, T.J.; Honigschmidt, N.A.; Nelson, D.L.; Bradley Wainscott, D.; Ahmad, L.J.; Shaw, J.; Threlkeld, P.G.; Wong, D.T.; Takeuchi, K. Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidiniylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4. Bioorg. Med. Chem. Lett. 2004, 14, 2653-2656.
98. 1A/2A receptorantagonist. In: Serotonin From the Molecule to the Clinic; Brain Res. Bull. (Serotonin Club Symposium edition), 2000, 117.
99. 2A receptor antagonist. In: Serotonin: From the Molecule to the Clinic; Brain Res. Bull. (Serotonin Club Symposium edition), 2000, 117.
100. 1A/2A receptor antagonist. In: Serotonin: From the Molecule to the Clinic; Brain Res. Bull. (Serotonin Club Symposium edition), 2000, 117.
101. 1A receptor antagonists with potent 5-HT reuptake inhibitory activity. Bioorg. Med. Chem. Lett. 2005, 15, 737-741.
102. 1B autoreceptor antagonist and 5-HT reuptake inhibitor in native tissue. Eur. J. Pharmacol. 2006, 536, 54-61.
103. 1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B. Psychopharmacol. 2007, 192, 121-133.
104. 1A receptor antagonists and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 1033-1036.
105. 1A activity and putative fast onset of antidepressant action. Soc. Neurosci. Abstr. 2003, 29, 958.16.
106. 1A activity and putative fast onset of antidepressant action. Soc. Neurosci. Abstr. 2003, 29, 958.17.
107. Poss, M.A.; Tortolani, D.R.; Mattson, R.J.; Yevich, J. P. Preparation of cyclic, amino-substituted N-aryl or N-heteroaryl cyclic amines as antidepressants. WO 2000044376 2000.
108. 1A receptor antagonist Soc. Neurosci. Abstr. 2003, 29, 958.15.
109. 1A receptor antagonist and an SSRI in vivo - effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 2005, 115, 1064-1070.
110. Lucki, I. Behavioural studies of serotonin receptor agonists as antidepressant drugs. J. Clin. Psychiatr. 1991, 52, 24-31.
111. Gould, E. Serotonin and hippocampal neurogenesis. Neuropsychopharmacol. 1999, 21, 46S-51S.
112. Malberg, J.E.; Eisch, A.J.; Nestler, E.J.; Duman, R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20, 9104-9110.
113. Schechter, L.E.; Bolanos, F.J.; Gozlan, H.; Lanfumey, L.; Haj-Dahmane, S.; Laporte, A.M.; Fattaccini, C.M.; Hamon, M. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: Biochemical and electrophysiological studies. J. Pharmacol. Exp. Ther. 1990, 255, 1335-1347.
114. 2 receptor-mediated behavior by continuous gepirone treatment. Life Sci. 1991, 49, 1777-1785.
115. 1A agonists in the treatment of depression? Biol. Psychiatr. 2003, 53, 193-203.
116. Fitton, A.; Benfield, P. Gepirone in depression and anxiety, disorders. CNS Drugs 1994, 1, 388-398.
117. Landon, M.; Eriksson, E.; Agren, H.; Fahlen, T. Effect of buspirone on sexual dysfubnction in depressed patients treated with selective serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 1999, 19, 268-273.
118. Michelson, D.; Bancroft, J.; Targum, S.; Kim, Y.; Tepner, R. Female sexual dysfunction associated with antidepressant administration: A randomized, placebo-controlled study of pharmacologic intervention. Am. J. Psychiatr. 2000, 157, 239-243.
119. Trivedi, M.H.; Fava, M.; Wisniewski, S.R.; Thase, M.E.; Quitkin, F.; Warden, D.; Ritz, L.; Nierenberg, A.A.; Lebowitz, B.D.; Biggs, M.M.; Luther, J.F.; Shores-Wilson, K.; Rush, A.J. STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 2006, 354, 1243-1252.
120. Martínez-Esparza, J.; Oficialdegui, A.M.; Pérez.-Silanes, S.; Heras, B.; Orús, L.; Palop, J.A.; Lasheras, B.; Roca, J.; Mourelle, M.; Bosch, A.; Del Castillo, J.C.;. Tordera, R.; Del Río, J.; Monge A. New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin, receptors and serotonin transporter, as a new class of antidepressants. J Med. Chem. 2001, 44, 418-428.
121. 1A serotonin receptors and serotonin transporter as a new class of antidepressants. Pharmazie 2004, 59, 499-501.
122. 1A receptor agonist. Neuropsychopharmacol. 2003, 28, 445-456.
123. 1A agonists and 5-HT reuptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity. Bioorg. Med. Chem. 2004, 12, 4843-4852.
124. 1A receptor agonistic properties. Eur. J. Pharmacol. 1997, 322, 147-153.
125. A receptor partial agonist. J Pharmacol. Exp. Therap. 2002, 302, 1220-1227.
126. 11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl. Med. Biol. 2002, 29, 509-515.
127. 1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur. J. Pharmacol. 2005, 510, 49-57
128. 1A partial agonist for the treatment of depression. IDrugs 2007, 10, 193-201.
129. Oshiro, Y.; Sakurai, Y.; Sato, S.; Kurahashi, N.; Tanaka, T.; Kikuchi, T,; Tottori, K.; Uwahodo, Y.; Miwa, T.; Nishi, T, 3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: Synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives. J. Med. Chem. 2000, 43, 177-189.
130. 1A receptors. Eur. J. Pharmacol. 2005, 517, 165-173.
131. A receptor agonist OPC-14523. Neuropharmacol. 2001, 41, 976-988.
132. Skuza, G.; Wedzony, K. Behavioral pharmacology of sigma-ligands. Pharmacopsychiatr. 2004, 37, S183-188.
133. Bermack, J.E.; Huddjeri, N.; Debonnel, G. Effects of the potential
134. Kodo, T.; Yagi, H.; Dan, A.; Masumoto, S.; Kinomura, N.; Koyama, K. Scrotonin reuptake inhibitor. WO 03053928, 2003.
135. Gross, J.L.; Mewshaw, R.E.; Stack G.P. Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4- pyridinyl-1Hindole. WO 03031439, 2003.
136. 1A or 5-HT reuptake site blockade. Neuropharmacol. 1999, 38, 1409-1419.
137. Hjorth, S.; Bengtsson, H.J.; Kullberg, A.; Carlzon, D.; Peilot, H.; Auerbach, S.B. Serotonin autoreceptor function and antidepressant drug action. J. Psychopharmacol. 2000, 14, 177-185.
138. 1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]- 1-[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4- yl]methanone hydrochloride): in vivo Neurochemical and behavioural evidence of anxiolytic activity. Neuropharmacol. 2006, 50, 975-983.
139. 1B receptor agonists 8-OH-DPAT and anpirtoline, as evidenced by use of the corresponding new and selective receptor antagonists NAD-299 and NAS-181. Br. J. Pharmacol. 1998, 125, 1733-43.
140. Millan, M.J.; Gobert, A.; Audinot, V.; Dekeyne, A.; Newman-Tancredi, A. Inverse agonists and serotonergic transmission: From recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo. Neuropsychopharmacol. 1999, 21, 61S-67S.
141. 1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. Eur. J. Pharmacol. 1999, 375, 359-365.
142. 1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br. J. Pharmacol. 1997, 121, 941-946.
143. 1B receptor inverse agonist SB-224289, potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. Ann. NY Acad. Sci. 1998, 861, 270-271.
144. 1B receptor antagonist. Bioorg. Med. Chem. Lett. 2005, 15, 4708-4712.
145. 1B receptor antagonist. Neuropharmacol. 2006, 50, 984-990.
146. 1B autoreceptor antagonist. Eur. J. Pharmacol. 2004, 499, 67-75.
147. 1B receptor antagonist, AR-A000002. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369, 330-337.
148. 1B antagonist. J. Pharmacol. Exp. Ther. 2003, 304, 1072-1084.
149. 1B/1D Antagonistic Activity: A New Approach toward Efficient Antidepressants. J. Med. Chem. 2000, 43, 1149-1157
150. 2 receptor antagonist properties. Eur. J. Pharmacol. 2001, 432, 9-17.
151. 1B/1D receptor antagonist: Effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat. Eur. J. Pharmacol. 2001, 432, 19-27.
152. 2C receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacol. 2004, 29, 1782-1789.
153. 1D antagonist activity: Chemistry and pharmacological evaluation of a series of thienopyran derivatives. Bioorg. Med. Chem. 2004, 12, 5277-5295.
154. 1D antagonists and 5-HT reuptake inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 3344-3348.
155. 1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test. Neuropsychopharmacol. 2007, 32, 2163-2172.
156. /B receptor antagonist and serotonin reuptake inhibitor SB-649915: Preclinical evidence for hastened onset of antidepressant/anxiolytic efficacy. CNS Drug Rev. 2007, 13, 206-223.
157. Hughes, Z.A.; Dawson, L.A. Differential autoreceptor control of extracellular 5-HT in guinea pig and rat: Species and regional differences. Psychopharmacol. 2004, 172, 87-93.
158. 1D receptor antagonist in native tissue. Br. J. Pharmacol. 2001, 133, 797-806.
159. 1 receptor ligands. Bioorg. Med. Chem. Lett. 2005, 15, 4370-4374.
160. 1B receptors modulate electroshock-induced generalised seizures in rats. Br. J. Pharmacol. 2005, 144, 628-635.
161. 1B antagonists as potential antidepressant drugs. Bioorg. Med. Chem. 1Lett. 2005, 15, 5567-5573.